

## Diabetes in pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update)

### Review Questions

*NICE guideline NG3*

*Review Questions*

*April 2026*



## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© NICE 2026. All rights reserved. Subject to [Notice of rights](#).

# Contents

1	Review Question.....	5
---	----------------------	---

# 1 Review Question

Review Question 1: In people with type 1 diabetes, who are planning to become pregnant, are pregnant, or are in the postpartum period, what is the effectiveness and cost-effectiveness of hybrid closed loop systems to improve maternal and fetal/neonatal outcomes, compared to standard insulin therapy?